Suspension of trading

NeuBase Therapeutics, Inc. Stock Nasdaq

NBSE

US64132K2015

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-10 EDT			5-day change	1st Jan Change
0.3780 ^USD	-3.20%		-.--%	-

25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

Valuation: NeuBase Therapeutics, Inc.

Market Cap	1.28M 1.11M 1.03M 966K 1.81M 121M 1.82M 12.24M 4.74M 59.35M 4.8M 4.69M 206M	P/E 2023 *	-	P/E 2024 *	-
Enterprise Value	1.28M 1.11M 1.03M 966K 1.81M 121M 1.82M 12.24M 4.74M 59.35M 4.8M 4.69M 206M	EV / Sales 2023 *	-	EV / Sales 2024 *	-
Free-Float	86.62%	Yield 2023 *	-	Yield 2024 *	-

* Estimated data More valuation ratios

Latest news : NeuBase Therapeutics, Inc.

25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI
24-06-27	NeuBase Therapeutics, Inc. Announces Board Resignations	CI
24-05-28	NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding	CI

More news

Managers and Directors: NeuBase Therapeutics, Inc.

Manager	Title	Age	Since
Ron Sarkar PRN	Corporate Officer/Principal	-	2021-10-31

Director	Title	Age	Since
Todd Branning BRD	Director/Board Member	56	2025-01-03

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUBASE THERAPEUTICS, INC.	-3.20%	-.--%	-	-	1.39M
LONZA GROUP AG	+1.44%	+1.71%	-10.63%	-9.16%	43.13B
REVOLUTION MEDICINES, INC.	+3.31%	+5.93%	+308.19%	+562.02%	34.65B
BEONE MEDICINES AG	+2.84%	+2.14%	+6.87%	+34.93%	30.03B
IQVIA HOLDINGS INC.	-1.70%	-7.54%	+8.51%	-22.34%	28B
CELLTRION, INC.	-1.90%	-1.56%	+11.62%	+19.80%	24.45B
ASCENDIS PHARMA A/S	-0.14%	+5.86%	-	-	14.34B
MEDPACE HOLDINGS, INC.	+0.68%	-1.53%	+52.04%	+107.47%	13.14B
EUROFINS SCIENTIFIC SE	-0.57%	-2.43%	+5.18%	+4.20%	12.53B
IONIS PHARMACEUTICALS, INC.	-0.26%	+1.15%	+100.27%	+80.69%	12.25B
Average	+0.05%	+0.73%	+60.26%	+97.20%	23.61B
Weighted average by Cap.	+0.77%	+1.27%	+65.22%	+113.23%

See all sector performances

NeuBase Therapeutics, Inc. is a United States-based preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâ€™s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâ€™s disease (HD), and oncology and in gene editing applications.

Employees

Sector

Biotechnology & Medical Research

More about the company